Analytical Data
-
Gene name
UBE2I
- Application
-
Alternative Names
UBE2I；UBC9；UBCE9；SUMO-conjugating enzyme UBC9
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P63279
-
Expression Region
1-157aa
-
AA Sequence
MSGIALSRLAQERKAWRKDHPFGFVAVPTKNPDGTMNLMNWECAIPGKKGTPWEGGLFKLRMLFKDDYPSSPPKCKFEPPLFHPNVYPSGTVCLSILEEDKDWRPAITIKQILLGIQELLNEPNIQDPAQAEAYTIYCQNRVEYEKRVRAQAKKFAP
-
Molecular Weight
44.9kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
UBE2I, also known as Ubiquitin-conjugating enzyme E2 I, is a critical member of the ubiquitin-proteasome system (UPS), which plays a fundamental role in regulating various cellular processes, including protein degradation, cell cycle progression, and responses to stress. UBE2I primarily functions by conjugating ubiquitin to target proteins, thereby marking them for degradation or modulating their activity and localization. Recent studies have highlighted its involvement in the regulation of key pathways associated with cancer, neurodegenerative disorders, and immune responses, making it a potential therapeutic target. Additionally, UBE2I is implicated in the modification of proteins involved in the DNA damage response, further emphasizing its importance in maintaining cellular homeostasis. The study of UBE2I as a recombinant protein has gained traction as researchers seek to elucidate its specific functions, interactions with various E3 ligases, and its contribution to disease pathology. Understanding the structure-function relationships of UBE2I and its regulatory mechanisms could provide insights for the development of novel therapeutic strategies, particularly in cancers where proteostasis is disrupted. Thus, the exploration of UBE2I in a recombinant form is essential for advancing our knowledge of ubiquitin signaling and its implications in health and disease.
